Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Raicevic, Sava (56816767800)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system-a one-decade single-centre experience
    (2016)
    Jelicic, Jelena (56180044800)
    ;
    Todorovic Balint, Milena (55773026600)
    ;
    Raicevic, Sava (56816767800)
    ;
    Ilic, Rosanda (56688276500)
    ;
    Stanisavljevic, Dejana (23566969700)
    ;
    Bila, Jelena (57208312102)
    ;
    Antic, Darko (23979576100)
    ;
    Balint, Bela (7005347355)
    ;
    Andjelic, Bosko (6507067141)
    ;
    Djurasinovic, Vladislava (35172762900)
    ;
    Sretenovic, Aleksandra (24170024700)
    ;
    Vukovic, Vojin (56180315400)
    ;
    Mihaljevic, Biljana (6701325767)
    Background and methods. The aim of the study was to evaluate retrospectively clinical course of 27 patients with primary central nervous system lymphoma (PCNSL) diagnosed and treated by different surgical approaches. Initial therapy-diagnostic approach included surgery with total tumour reduction (TTR) performed in 12 patients (44.4%), while partial reduction and biopsy were performed in 8 (29.7%) and 7 (25.9%) patients, respectively. All patients were treated with chemotherapy based on high-dose methotrexate (HD-MTX) with/without whole-brain radiotherapy (WBRT). Results. The median overall survival (OS) and event-free survival were 37 and 31 months, respectively, with overall response rate of 74%. The patients who underwent an open surgery with TTR had significantly longer OS (median not reached), comparing with partial tumour reduction or biopsy only (Log-Rank χ2 6.08, p = 0.014) when median OS was 23 months. In patients with performance status according to Eastern Cooperative Oncology Group (ECOG PS) ≥ 3, OS was 23 months, contrary to ECOG PS 1-2 when median was not reached. The International Extranodal Lymphoma Study Group score (low, intermediate and high) also influenced OS between three risk groups (Log-Rank χ2 12.5, p = 0.002). Conclusion. The treatment of PCNSL still remains doubtful, however possible benefit from the TTR followed with HD-MTX with/without WBRT should be reconsidered. © 2015 The Neurosurgical Foundation.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback